No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ATXS240816P7500
- 0.05
- -0.30-85.71%
15min DelayClose Jul 22 15:54 ET
0.05High0.05Low
0.05Open0.35Pre Close50 Volume3 Open Interest7.50Strike Price250.00Turnover103.87%IV36.70%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0355Delta0.0244Gamma235.40Leverage Ratio-0.0049Theta-0.0003Rho-8.36Eff Leverage0.0024Vega
Intraday
- 5D
- Daily
News
Express News | Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the
Astria Therapeutics Is Maintained at Outperform by Oppenheimer
Astria Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Astria Therapeutics : Oppenheimer Cuts Target Price to $25 From $29
Comments
» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
8
$Astria Therapeutics Inc(ATXS.US$ Astria Therapeutics Enters Worldwide Exclusive License Agreement With Ichnos Sciences For An OX40 Portfolio; To Pay Ichnos One-time Upfront License Fee Of $15M, Up To $305M In Milestones
Moomoo 24/7· 17 mins ago![]()
Moomoo 24/7· 17 mins ago
1
Read more